Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16835312 | 0.87 | LMNA (0.49) | LMNAMAOBHTR1ADRD2HTR2A | |
| SCHEMBL3923772 | 0.87 | MAOB (0.53) | LMNAGAAPKMMAOBHTR1A | |
| SCHEMBL13675019 | 0.85 | LMNA (0.53) | LMNAMAOBHTR1ADRD2HTR2A | |
| SCHEMBL16174315 | 0.83 | LMNA (0.51) | LMNAMAOBHTR1ADRD2HTR2A | |
| SCHEMBL10264577 | 0.82 | LMNA (0.50) | LMNAMAOBHTR1ADRD2HTR2A | |
| SCHEMBL9132334 | 0.80 | KDM4E (0.58) | LMNAGAAMAOBHTR1ADRD2 | |
| SCHEMBL5327794 | 0.78 | MAOB (0.49) | LMNAMAOBHTR1ADRD2HTR2A | |
| SCHEMBL6379970 | 0.78 | LMNA (0.46) | LMNAMAOBHTR1ADRD2HTR2A | |
| SCHEMBL30692234 | 0.77 | LMNA (0.56) | LMNAGAAMAOBMAPTTP53 | |
| SCHEMBL1639030 | 0.77 | LMNA (0.56) | LMNAGAAMAOBMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514457-B2 | Substituted aryloxymethyl bicyclicmethyl acetamide compounds | PFIZER INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20060270682-A1 | Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds | PFIZER, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2005024755-A2 | MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS OR DIABETES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270682-A1 | Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds | NR0B1, NR0B2, NR2C2 | LMNA 2592/4885GAA 4823/4885PKM 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.